Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why do we need another antiemetic? Just ask.

× No keyword cloud information.

11 in total

1. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials.

Authors: Niels Neymark; Ralph Crott
Journal: Support Care Cancer Date: 2005-04-15 Impact factor: 3.603

2. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy.

Authors: Jason M Jones; Rui Qin; Aditya Bardia; Breanna Linquist; Sherry Wolf; Charles L Loprinzi
Journal: J Palliat Med Date: 2011-05-09 Impact factor: 2.947

3. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.

Authors: Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher
Journal: Support Care Cancer Date: 2005-02-08 Impact factor: 3.603

4. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors: Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603

Review 5. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.

Authors: Rudolph M Navari
Journal: Drugs Date: 2013-03 Impact factor: 9.546

Review 6. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors: Rudolph M Navari
Journal: Drugs Date: 2009 Impact factor: 9.546

Review 7. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.

Authors: Toni M Dando; Caroline M Perry
Journal: Drugs Date: 2004 Impact factor: 9.546

8. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.

Authors: Thomas A Burke; Tami Wisniewski; Frank R Ernst
Journal: Support Care Cancer Date: 2010-01-26 Impact factor: 3.603

Review 9. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.

Authors: Rudolph M Navari
Journal: Biomed Res Int Date: 2015-09-03 Impact factor: 3.411

10. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Authors: Yolanda Escobar; Gerardo Cajaraville; Juan Antonio Virizuela; Rosa Álvarez; Andrés Muñoz; Olatz Olariaga; María José Tamés; Begoña Muros; María Jose Lecumberri; Jaime Feliu; Purificación Martínez; Juan Carlos Adansa; María José Martínez; Rafael López; Ana Blasco; Pere Gascón; Virginia Calvo; Pablo Luna; Joaquín Montalar; Patricia Del Barrio; María Victoria Tornamira
Journal: Support Care Cancer Date: 2015-06-17 Impact factor: 3.603